Abstract Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of
the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV)
infection, the integrase strand transfer inhibitors. Integrase strand transfer inhibitors are
potent inhibitors of the HIV integrase enzyme with IC 90/95 values in the low nanogram per
milliliter range and they retain antiviral activity against strains of HIV with acquired resistance
to other classes of antiretrovirals. Each of the integrase strand transfer inhibitors have …

Abstract Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the
latest class of antiretrovirals (ARVs) that have become available to treat human
immunodeficiency virus (HIV) infection: integrase strand transfer inhibitors (INSTIs). INSTIs
are potent inhibitors of the HIV integrase enzyme, with protein binding–adjusted
concentration inhibiting viral replication by 90/95%[IC 90/95] values in the low nanogram per
millilitre range, and they retain antiviral activity against strains of HIV with acquired …